14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close May 04, 2026
MIGI vs EKSO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of May 04, 2026, Ekso Bionics Holdings, Inc. (EKSO) is the stronger overall head-to-head candidate over Mawson Infrastructure Group Inc. (MIGI) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MIGI carries a Unified Composite Score of 56.4/100 (HOLD) at $4.71 (5.5x Forward P/E, -456.2% operating margin), whereas EKSO carries 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MIGI vs EKSO. Trailing 12-month operating profitability (MIGI -456.2% vs EKSO -119.7%) and valuation multiples (MIGI 5.5x vs EKSO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Instruments & Supplies value chain with $42.0M market capitalization and -119.7% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ MIGI vs EKSO Key Questions & Quantitative Answers
As of May 04, 2026, Ekso Bionics Holdings, Inc. (EKSO) is the stronger overall head-to-head candidate over Mawson Infrastructure Group Inc. (MIGI) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MIGI carries a Unified Composite Score of 56.4/100 (HOLD) at $4.71 (5.5x Forward P/E, -456.2% operating margin), whereas EKSO carries 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin). Technically, MIGI sits in a Neutral phase (RSI 49.5, UNCLASSIFIED options structure) and EKSO sits in a Markup phase (RSI 60.4, UNCLASSIFIED options structure).
EKSO leads the Growth & Scale pillar: MIGI posts -78.5% YoY revenue growth and -97.7% YoY earnings growth on $40M TTM revenue (43.6% gross margin, -456.2% operating margin), compared with EKSO at -38.3% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (53.5% gross margin, -119.7% operating margin). On trailing 12-month operating scale, MIGI generates $40M in USD-normalized revenue versus $13M for EKSO. In operating R&D and SG&A reinvestment, MIGI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EKSO.
MIGI screens cheaper on headline valuation multiples. MIGI trades at 5.5x Forward P/E, 5.5x Trailing P/E, N/M PEG, and 1.3x EV/Revenue (-59.6% FCF margin), whereas EKSO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.3x EV/Revenue (-86.0% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MIGI (-461.2% ROE) versus EKSO (-107.6% ROE) capital efficiency.
In options market volatility and institutional positioning, MIGI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (13.79β · 314% Vol realized risk). By comparison, EKSO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.16β · 76% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of May 04, 2026. For educational research only; not investment advice.